News + Resources
What They Are Saying: FTC’s Final HSR Premerger Rules Place Undue Burden on Competitive M&A Across Life Sciences
Leading organizations are expressing concern about the impact of the Federal Trade Commission (FTC)’s final Hart-Scott-Rodino (HSR) premerger notification rule, including the chilling effect it could have on biopharmaceutical and life sciences innovation. While the...
PULSE Campaign Statement on Final HSR Rules
Washington, D.C. – In response to the final Hart-Scott-Rodino (HSR) premerger notification rules released today by the Federal Trade Commission (FTC), the Partnership for the U.S. Life Science Ecosystem (PULSE) released the following statement: While we appreciate...
Bloomberg Law: “Chilling Effect” of FTC & DOJ’s Aggressive M&A Enforcement Approach
The Federal Trade Commission (FTC) and Department of Justice (DOJ)’s aggressive approach towards mergers and acquisitions (M&A) is deterring companies from pursuing deals, write Bloomberg Law reporters Justin Wise and Mahira Dayal – threatening even procompetitive...
Innovations Advanced by M&A: A First-In-Class Treatment for Hypertrophic Cardiomyopathy
Mergers and acquisitions (M&A) are a vital mechanism for transitioning treatments currently in development to approved medicines available to the patients who need them the most. In one such example, the synergies from a life science acquisition brought a revolutionary therapy for hypertrophic cardiomyopathy (HCM) to patients.
Concurrences Law & Economics: Life Sciences M&A Brings Together Complementary Resources, Expertise
For life science companies of all sizes, competitive mergers and acquisitions (M&A) serve as a critical driver in bringing new and groundbreaking treatments and cures to market. In a recent article published in Concurrences Law and Economics, economists from...